Literature DB >> 30411161

Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma.

R Bücker1, C Schaefer2, A D Gruber3, J Hoppe3, L Lazzerini2, J Barinoff2, J Sehouli2, Günter Cichon4.   

Abstract

PURPOSE: The identification of novel cell lines which combine the most important properties of mucosal membranes in terms of drug absorption, transmembrane transport and mucus secretion can help to establish improved and meaningful test systems for pharmacological and infectiological studies.
METHODS: We have established a novel mucus secreting tumor cell line (Cx-03) derived from a female patient who underwent radical hysterectomy after diagnosis of a large malignant carcino sarcoma (Muellerian mixed tumor). Via xenotransplantation in SCID beige mice, recultivation and subcloning a stable cell line was established from primary tumor cells.
RESULTS: Human origin and novelty of the cell line was determined by karyotype analysis and STR fingerprint. During growth cells produce considerable amounts of a PAS positive viscoelastic mucus. Immunostaining revealed expression of mucins and the mucin modifier CLCA1. We demonstrate in initial electrophysiological experiments that confluent, polarized monolayers of Cx-03 are formed (on PCF-filter supports) that exhibit stable electrical resistance (> 600 Ω cm2). Confluent Cx-03 monolayers express barrier-forming tight junction proteins claudin-1 and -4 which co-localize with zonula occludens protein-1 (ZO-1) at cell-cell contacts.
CONCLUSIONS: Mucus secretion is a rare property among mammalian cell lines. In combination with its ability to form polarized monolayers Cx-03 might contribute as a novel cell based model for drug absorption, transport and barrier studies.

Entities:  

Keywords:  CLCA1; MUC2; barrier function; mucus screting cell line

Mesh:

Substances:

Year:  2018        PMID: 30411161     DOI: 10.1007/s11095-018-2533-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

Review 1.  A vaginal fluid simulant.

Authors:  D H Owen; D F Katz
Journal:  Contraception       Date:  1999-02       Impact factor: 3.375

2.  Expression of specific markers and particle transport in a new human intestinal M-cell model.

Authors:  E Gullberg; M Leonard; J Karlsson; A M Hopkins; D Brayden; A W Baird; P Artursson
Journal:  Biochem Biophys Res Commun       Date:  2000-12-29       Impact factor: 3.575

3.  Drug and gene delivery to mucosal tissues: the mucus barrier. Preface.

Authors:  Justin Hanes; Jo Demeester
Journal:  Adv Drug Deliv Rev       Date:  2009-02-27       Impact factor: 15.470

4.  Rapid isolation of genomic DNA from animal tissues.

Authors:  G Konat; G Gantt; I Laszkiewicz; E L Hogan
Journal:  Exp Cell Res       Date:  1990-10       Impact factor: 3.905

5.  From 48 to 46: cytological technique, preconception, and the counting of human chromosomes.

Authors:  M J Kottler
Journal:  Bull Hist Med       Date:  1974       Impact factor: 1.314

6.  In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients.

Authors:  Carolien Grammen; Patrick Augustijns; Joachim Brouwers
Journal:  Antiviral Res       Date:  2012-09-20       Impact factor: 5.970

7.  Interactions of microbicide nanoparticles with a simulated vaginal fluid.

Authors:  José das Neves; Cristina M R Rocha; Maria Pilar Gonçalves; Rebecca L Carrier; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Mol Pharm       Date:  2012-10-08       Impact factor: 4.939

Review 8.  Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.

Authors:  V L Baker
Journal:  Obstet Gynecol Clin North Am       Date:  1994-06       Impact factor: 2.844

Review 9.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.

Authors:  Samuel K Lai; Ying-Ying Wang; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2008-12-13       Impact factor: 15.470

10.  In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine.

Authors:  José das Neves; Francisca Araújo; Fernanda Andrade; Johan Michiels; Kevin K Ariën; Guido Vanham; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Mol Pharm       Date:  2013-06-17       Impact factor: 4.939

View more
  1 in total

1.  Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.

Authors:  Lea Lazzerini; Korinna Jöhrens; Jalid Sehouli; Günter Cichon
Journal:  Arch Gynecol Obstet       Date:  2020-08-19       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.